PML at Mitochondria-Associated Membranes Is Critical for the Repression of Autophagy and Cancer Development
Author(s) -
Sonia Missiroli,
Massimo Bonora,
Simone Patergnani,
Federica Poletti,
Mariasole Perrone,
Roberta Gafà,
Eros Magri,
Andrea Raimondi,
Giovanni Lanza,
Carlo Tacchetti,
Guido Kroemer,
Pier Paolo Pandolfi,
Paolo Pinton,
Carlotta Giorgi
Publication year - 2016
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2016.07.082
Subject(s) - autophagy , promyelocytic leukemia protein , microbiology and biotechnology , downregulation and upregulation , suppressor , mitochondrion , cancer cell , biology , apoptosis , programmed cell death , autophagosome , repressor , cancer research , chemistry , acute promyelocytic leukemia , cancer , cell culture , biochemistry , gene expression , gene , genetics , retinoic acid
The precise molecular mechanisms that coordinate apoptosis and autophagy in cancer remain to be determined. Here, we provide evidence that the tumor suppressor promyelocytic leukemia protein (PML) controls autophagosome formation at mitochondria-associated membranes (MAMs) and, thus, autophagy induction. Our in vitro and in vivo results demonstrate how PML functions as a repressor of autophagy. PML loss promotes tumor development, providing a growth advantage to tumor cells that use autophagy as a cell survival strategy during stress conditions. These findings demonstrate that autophagy inhibition could be paired with a chemotherapeutic agent to develop anticancer strategies for tumors that present PML downregulation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom